Market cap
$1.9b
End-of-day close multiplied by current shares on issue.
Result releasedAnnolyse analysis published
The restated comparison separates the tax charge, property fair-value movements, operating performance and resident cash flows.
Revenue context before the current result.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Statutory profit after tax across covered periods.
Market context
These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.
The latest close and share count context for the market price.
Market cap
$1.9b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
16.57x
Market cap compared with recent free cash flow.
P/B
0.46x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY25 vs FY24
Revenue
n/m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Net profit after tax
−$436.8m
Caveat: metric quality flags apply; use this value with basis context.
Net cash inflow from operating activities
$410.3m
Caveat: metric quality flags apply; use this value with basis context.
Full-year dividend per share
0.0c
Caveat: metric quality flags apply; use this value with basis context.
EBITDAF
$45.5m
Caveat: metric quality flags apply; use this value with basis context.
Profit before tax
−$215.4m
Caveat: metric quality flags apply; use this value with basis context.
Cash and cash equivalents
$17.7m
-57.8% ↓ vs $41.8m
Total assets
n/m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Analysis ofRYM FY25Result releasedAnnolyse analysis published
What changed
The pre-tax loss narrowed to NZ$215.4m from NZ$281.9m, while the after-tax loss widened to NZ$436.8m from NZ$169.7m. These are comparisons against the current report's restated prior-year figures. The profit before tax margin improved by 12.6 percentage points, from -40.9% to -28.3%; that measure includes the property fair-value movements and impairment charges discussed below.
The tax line changed from a NZ$112.3m credit to a NZ$221.4m expense. The different direction of the pre-tax and after-tax loss comparisons therefore needs that explicit tax context, rather than a claim that the after-tax movement alone measures operating performance.
What matters
Impairment losses were NZ$172.9m, compared with NZ$96.5m. The company's separately defined profit before tax and fair-value movements remained a loss of NZ$384.6m, compared with a NZ$242.8m loss.
The company also reports non-GAAP operating EBITDAF of NZ$45.5m, compared with restated NZ$14.8m. That operating measure has a different definition from statutory pre-tax profit and net profit. The figures should retain their distinct labels and should not be treated as interchangeable measures of the result.
Expectations
None alone establishes the future level of operating earnings, property valuations or taxable profit.
No new numerical earnings, funding or distribution forecast is inferred from these actuals. An outlook assessment requires the relevant operational assumptions and the company's specifically stated guidance for the next period.
Quality of result
Ryman's cash flows include resident occupation-right receipts, repayments and refundable accommodation deposits. This operating cash total should therefore not be interpreted as ordinary industrial-company EBITDA cash conversion.
Closing cash was NZ$17.7m. The face value of loans and borrowings was NZ$1.7b, compared with NZ$2.6b on the same face-value basis. The cash-flow statement separately records net equity-raising proceeds of NZ$970.2m and loan repayments; the financing transactions are distinct from trading profit.
Net trade receivables were NZ$22.1m, compared with restated NZ$21.7m. The much larger trade-and-other-receivables balance includes occupancy advances, refundable accommodation deposits and prepayments, and should not be substituted for actual trade debtors. No dividends were declared or paid during FY25 or FY24.
Unresolved
How will care and village operations develop separately from property fair values and impairment charges? How will resident cash receipts, repayments and the development programme affect future funding needs? What future taxable-profit assumptions support the tax position? These questions require their own source evidence; the current positive operating cash inflow and the non-GAAP operating measure do not by themselves settle them.
Chat
Ask follow-up questions about Ryman Healthcare's FY25 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
FY25 company presentation with restatedFY24 OperatingEBITDAF/NTA
FY25 / results presentationFY25 consolidated statements
FY25 / financial reportFY24 restated comparative inFY25 consolidated statements
FY24 / financial reportFY25 company presentation with restatedFY24 OperatingEBITDAF/NTA
FY24 / results presentationRelated insights
Compare this result's metrics with other covered NZX companies.
Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.